The AHA expressed concerns June 10 to the Centers for Medicare & Medicaid Services about its proposed Transforming Episode Accountability Model (TEAM), saying it "is proposing to mandate a model that has significant design flaws, and as proposed, places too much risk on providers with too little opportunity for reward in the form of shared savings, especially considering the significant upfront investments required." The proposed mandatory payment model would bundle payment to acute care hospitals for five types of surgical episodes, which comprise over 11% of inpatient prospective payment system payments (not including outpatient payments that would also be at risk in the model). The association urged CMS to make model participation voluntary, reduce the discount factor from 3% to no more than 1%, and make several significant changes to design elements, otherwise CMS should not implement the model. “If CMS cannot make extensive changes to the model, it should not implement it at this time,” AHA wrote. “To do so would make TEAM no more than a thinly disguised payment cut, as it fails to provide hospitals a fair opportunity to achieve enough savings to garner a reconciliation payment.”

Related News Articles

Headline
The Department of Health and Human Services Health Resources and Services Administration is accepting applications until April 22 for its four-year Rural…
Headline
The Centers for Medicare & Medicaid Services announced Jan. 15 that 53.4% of people with Traditional Medicare are in an accountable care relationship with…
Headline
The AHA's Advancing Health podcast recently celebrated the end of 2024 by releasing highlights from some of its most popular episodes of the year. The roundup…
Headline
The Centers for Medicare & Medicaid Services Dec. 20 solicited an additional 10 participants for its Rural Community Hospital Demonstration program. This…
Headline
The Health Resources and Services Administration last week directed Sanofi to cease implementation of its 340B rebate proposal immediately and to inform HRSA…
Headline
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023.…